Abstract #2637

Targeted MRI contrast guided drug delivery: Magnevist and doxorubicin encapsulated into liposomes for detection and treatment of glioma

Xiaoli Liu¹, A. B. Madhankumar², Patti A. Miller¹, Becky Webb², James R. Connor², and Qing X. Yang¹

¹Radiology, College of Medicine Penn State University, Hershey, PA, United States, ²Neurosurgery, College of Medicine Penn State University, Hershey, PA, United States

Glioma in its early stage is hard to detect and treat because MRI contrast agent and chemotoxin are not able to cross the blood brain barrier (BBB). The conventional MRI contrast agent such as Magnevist (GD-DTPA) is limited to the cases where the BBB is significantly compromised by the tumor. Present study reports the development of a novel theranostic tool, interleukin-13-liposomes-Magnevist-doxorubicine (IL-13-lip-magnevist-dox) for detection and treatment of glioma. Our results demonstrated that IL-13-lip-magnevist-dox own the potential to specifically target, concomitantly detect and treat glioma in its early stage when BBB is still intact.

This abstract and the presentation materials are available to members only; a login is required.

Join Here